A Phase 1, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs Ganitumab (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 29 Jun 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 29 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.